Sproutly Canada Inc. - die wird der Renner! (Seite 36)
eröffnet am 15.10.18 16:50:05 von
neuester Beitrag 27.03.24 21:47:18 von
neuester Beitrag 27.03.24 21:47:18 von
Beiträge: 1.145
ID: 1.290.591
ID: 1.290.591
Aufrufe heute: 3
Gesamt: 79.665
Gesamt: 79.665
Aktive User: 0
ISIN: CA85209J1084 · WKN: A2JQU9
0,0226
EUR
-6,61 %
-0,0016 EUR
Letzter Kurs 13.10.20 Tradegate
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7000 | +75,00 | |
| 4,7400 | +41,92 | |
| 1,8200 | +34,81 | |
| 1,0000 | +33,33 | |
| 15,348 | +19,53 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5189 | -11,75 | |
| 7,0000 | -12,50 | |
| 0,8040 | -24,15 | |
| 0,7800 | -29,73 | |
| 5,0100 | -90,93 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 65.231.161 von Kosto23 am 30.09.20 01:03:58Das faszinierende ist aber, das Sproutly wieder und wieder und wieder eine private loan o.ä. bekommt! Vorzugsweise vom IBS Besitzer Dr Arup Sen.
Also von der rechten in die linke Tasche.
Ich frage mich wie lange das noch so weiter geht und ob Sproutly je etwas vom Gewinn abhaben wird.🤔
Also von der rechten in die linke Tasche.
Ich frage mich wie lange das noch so weiter geht und ob Sproutly je etwas vom Gewinn abhaben wird.🤔
Oh je, wir müssen bibbern, dass die nicht pleite gehen. Der Geschäftsbericht liest sich nicht besonders gut. Das Geld wird allmählich knapp ...
https://finance.yahoo.com/news/sproutly-announces-financial-…
Sproutly Canada, Inc. (CSE: SPR) (FRA: 38G) (OTCQB: SRUTF) ("Sproutly" or the "Company") today announced the Company’s financial results for the first quarter ended May 31, 2020.
"We have continued to make progress with our Business Transformation Plan through the first quarter of this year despite the ongoing impact of the COVID-19 pandemic." said Dr. Arup Sen, Chief Executive Officer of Sproutly. "We are now able to leverage the success of Infusion BioSciences Inc. who has launched beverages using hemp Infuz2O in the US market with Kalo sparkling beverage and RI JUICE fresh fruit juices, to focus on using cannabis Infuz2O and BioNatural oils in unique Cannabis 2.0 products in Canada followed by other international markets."
Highlights for the First Quarter Ended May 31, 2020
THR entered into cannabis supply agreements with the provinces of Manitoba and Saskatchewan, through the Manitoba Liquor and Lotteries Corporation and the Saskatchewan Liquor and Gaming Authority, respectively. These are the 3rd and 4th provinces in Canada to carry the Company’s CALIBER branded indoor-grown dried flower products.
The Company amended the conversion price of its previously issued convertible debentures from a price of $0.75 per common share to $0.105 per share.
The Company commenced a Business Transformation Plan. The key aspects are:
Appointing Dr. Arup Sen as CEO, replacing Keith Dolo
Implementing a reduction in its staffing by 75% and cutback in cultivation output
Infusion Biosciences has provided a letter of intent to invest up to an additional a$855,000. The investment will be made by way of issuance of convertible debentures (the "Convertible Debentures"). The Convertible Debentures will bear an accrued interest rate of 15% and be exchangeable into units at a price of $0.07 per unit (the "Units"). The Units consist of one common share and one common share purchase warrant, with each warrant allowing the holder to purchase one common share at a price of $0.08.
Subsequent Events
The Company reorganized their Board of Directors. Michael Bellas, Gregg Orr and Justin Kates departed, with Craig Loverock and Paul Marcellino joining the Board. In addition, Con Constandis was named Chair of the Audit Committee with Dr. Arup Sen taking over as Board Chairman.
THR entered into a cannabis supply agreement with the province of British Columbia through the British Columbia Liquor Distribution Branch as well as completing initial sales into the province. This is the 5th province in Canada to carry the Company’s CALIBER branded indoor-grown dried flower products.
The Company amended the interest clause on its previously issued convertible debentures such that the Company can now settle the interest owing through the issuance of common shares or cash, subject to the prior written approval of Debenture holders holding more than 20% of the outstanding Debentures.
The Company secured a private loan of $855,000 from Infusion Biosciences Inc., a related party of the Company. The Loan carries an interest rate of 15% per annum accruing and compounding monthly, payable on maturity on or before October 24, 2020 (the "Maturity Date").
The Company completed a non-brokered private placement of 1,500,000 units of the Company at a price of $0.07 per Equity Unit to raise gross proceeds of $105,000. Each Equity Unit consists of one Common Share and one Warrant, with each Warrant entitling the holder to acquire one Warrant Share at an exercise price equal to $0.08 for a period of two years from date of issuance.
The Company completed a settlement of outstanding current debt of the Company in the amount of $180,000 with an arm’s length creditor. In settlement of the Debt, the Company has issued 1,800,000 Common Shares (the "Settlement Shares") at a price of $0.10 per Settlement Share.
The Company settled an aggregate of $182,340 of payroll indebtedness owed to certain current and former employees for past services rendered through the issuance of 2,604,867 common shares at a deemed issuance price of $0.07 per share.
The Company amended maturity date of its previously issued convertible debentures from October 24, 2020 to April 24, 2021 and reduced the conversion price from $0.105 to $0.06 per share.
Consolidated Financial Statements and Management's Discussion and Analysis
Sproutly Canada, Inc. (CSE: SPR) (FRA: 38G) (OTCQB: SRUTF) ("Sproutly" or the "Company") today announced the Company’s financial results for the first quarter ended May 31, 2020.
"We have continued to make progress with our Business Transformation Plan through the first quarter of this year despite the ongoing impact of the COVID-19 pandemic." said Dr. Arup Sen, Chief Executive Officer of Sproutly. "We are now able to leverage the success of Infusion BioSciences Inc. who has launched beverages using hemp Infuz2O in the US market with Kalo sparkling beverage and RI JUICE fresh fruit juices, to focus on using cannabis Infuz2O and BioNatural oils in unique Cannabis 2.0 products in Canada followed by other international markets."
Highlights for the First Quarter Ended May 31, 2020
THR entered into cannabis supply agreements with the provinces of Manitoba and Saskatchewan, through the Manitoba Liquor and Lotteries Corporation and the Saskatchewan Liquor and Gaming Authority, respectively. These are the 3rd and 4th provinces in Canada to carry the Company’s CALIBER branded indoor-grown dried flower products.
The Company amended the conversion price of its previously issued convertible debentures from a price of $0.75 per common share to $0.105 per share.
The Company commenced a Business Transformation Plan. The key aspects are:
Appointing Dr. Arup Sen as CEO, replacing Keith Dolo
Implementing a reduction in its staffing by 75% and cutback in cultivation output
Infusion Biosciences has provided a letter of intent to invest up to an additional a$855,000. The investment will be made by way of issuance of convertible debentures (the "Convertible Debentures"). The Convertible Debentures will bear an accrued interest rate of 15% and be exchangeable into units at a price of $0.07 per unit (the "Units"). The Units consist of one common share and one common share purchase warrant, with each warrant allowing the holder to purchase one common share at a price of $0.08.
Subsequent Events
The Company reorganized their Board of Directors. Michael Bellas, Gregg Orr and Justin Kates departed, with Craig Loverock and Paul Marcellino joining the Board. In addition, Con Constandis was named Chair of the Audit Committee with Dr. Arup Sen taking over as Board Chairman.
THR entered into a cannabis supply agreement with the province of British Columbia through the British Columbia Liquor Distribution Branch as well as completing initial sales into the province. This is the 5th province in Canada to carry the Company’s CALIBER branded indoor-grown dried flower products.
The Company amended the interest clause on its previously issued convertible debentures such that the Company can now settle the interest owing through the issuance of common shares or cash, subject to the prior written approval of Debenture holders holding more than 20% of the outstanding Debentures.
The Company secured a private loan of $855,000 from Infusion Biosciences Inc., a related party of the Company. The Loan carries an interest rate of 15% per annum accruing and compounding monthly, payable on maturity on or before October 24, 2020 (the "Maturity Date").
The Company completed a non-brokered private placement of 1,500,000 units of the Company at a price of $0.07 per Equity Unit to raise gross proceeds of $105,000. Each Equity Unit consists of one Common Share and one Warrant, with each Warrant entitling the holder to acquire one Warrant Share at an exercise price equal to $0.08 for a period of two years from date of issuance.
The Company completed a settlement of outstanding current debt of the Company in the amount of $180,000 with an arm’s length creditor. In settlement of the Debt, the Company has issued 1,800,000 Common Shares (the "Settlement Shares") at a price of $0.10 per Settlement Share.
The Company settled an aggregate of $182,340 of payroll indebtedness owed to certain current and former employees for past services rendered through the issuance of 2,604,867 common shares at a deemed issuance price of $0.07 per share.
The Company amended maturity date of its previously issued convertible debentures from October 24, 2020 to April 24, 2021 and reduced the conversion price from $0.105 to $0.06 per share.
Consolidated Financial Statements and Management's Discussion and Analysis
Antwort auf Beitrag Nr.: 65.012.484 von Wolgastae am 07.09.20 19:49:50bei diesen cannabis drecksläden kann alles sein. ich habe noch aurora, sproutly und dixie im depot. die behalte ich einfach in der hoffnung dass man mal break even aussteigt. ich investiere keinen cent mehr in canna drecksbuden.
Antwort auf Beitrag Nr.: 65.012.448 von realchoice am 07.09.20 19:45:23Aber Sproutly verdient kaum was...
Aktuell wird nur Edel-Cannabis unter der Marke „Caliber“ verkauft.
Vll will IBS die Schulden später wieder in Aktien umwandeln?
Und so Stück für Stück Sproutly übernehmen? Kann das sein?
Aktuell wird nur Edel-Cannabis unter der Marke „Caliber“ verkauft.
Vll will IBS die Schulden später wieder in Aktien umwandeln?
Und so Stück für Stück Sproutly übernehmen? Kann das sein?
Trading Spotlight
Antwort auf Beitrag Nr.: 65.002.161 von Mister10K am 06.09.20 12:47:18viell. will die tochterfirma sproutly noch etwas melken bevor der laden dicht macht.
Antwort auf Beitrag Nr.: 65.002.161 von Mister10K am 06.09.20 12:47:18Schon seltsam... IBS hat mit Kalo und Kalo mit Pepsi starke Partner, Gleichzeitig kriegt Sproutly nichts gebacken, bekommt aber dennoch immer wieder Cash von seiner „Tochterfirma“. 🤔
Antwort auf Beitrag Nr.: 64.995.342 von Wolgastae am 04.09.20 21:08:12
hi Wolgastae, ich habe es mal durch den ÜS gejagt: der rot markierte Satz ist auffällig
httVANCOUVER, Britisch-Kolumbien - (BUSINESS WIRE) - Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) („Sproutly“ oder das „Unternehmen“) freut sich bekannt zu geben, dass es sich einen gesichert hat Privatkredit (der „Kredit“) in Höhe von 855.000 USD von Infusion Biosciences Inc. (der „Kreditgeber“), einer verbundenen Partei des Unternehmens (der „Schuldenfinanzierung“). Der Kredit wird mit einem Zinssatz von 15% pa aufgelaufen und zusammengesetzt monatlich, zahlbar bei Fälligkeit am oder vor dem 24. Oktober 2020 (dem „Fälligkeitsdatum“). Das Unternehmen rechnet damit, den Erlös aus der Schuldenfinanzierung zur Unterstützung des allgemeinen Betriebskapitals des Unternehmens zu verwenden.ps://www.businesswire.com/news/ home / 20200827005784 / de /
meiner Meinung nach müssen die echt klamm sein, wenn die sich von ihrer Tochterfirma Geld leihen zu 15%pa bei monatlichen Raten....
hätten die nicht auf dem freien Markt zu deutlich günstigeren Konditionen sich Geld leihen können oder sind sie schon so insolvent, dass ihnen keiner mehr Geld leihen will...
Zitat von Wolgastae: Vielleicht kannst du deine Meinung zur letzte Meldung beitragen.
Ich kanns nicht einordnen...
hi Wolgastae, ich habe es mal durch den ÜS gejagt: der rot markierte Satz ist auffällig
httVANCOUVER, Britisch-Kolumbien - (BUSINESS WIRE) - Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) („Sproutly“ oder das „Unternehmen“) freut sich bekannt zu geben, dass es sich einen gesichert hat Privatkredit (der „Kredit“) in Höhe von 855.000 USD von Infusion Biosciences Inc. (der „Kreditgeber“), einer verbundenen Partei des Unternehmens (der „Schuldenfinanzierung“). Der Kredit wird mit einem Zinssatz von 15% pa aufgelaufen und zusammengesetzt monatlich, zahlbar bei Fälligkeit am oder vor dem 24. Oktober 2020 (dem „Fälligkeitsdatum“). Das Unternehmen rechnet damit, den Erlös aus der Schuldenfinanzierung zur Unterstützung des allgemeinen Betriebskapitals des Unternehmens zu verwenden.ps://www.businesswire.com/news/ home / 20200827005784 / de /
meiner Meinung nach müssen die echt klamm sein, wenn die sich von ihrer Tochterfirma Geld leihen zu 15%pa bei monatlichen Raten....
hätten die nicht auf dem freien Markt zu deutlich günstigeren Konditionen sich Geld leihen können oder sind sie schon so insolvent, dass ihnen keiner mehr Geld leihen will...
Antwort auf Beitrag Nr.: 64.995.126 von Mister10K am 04.09.20 20:48:07Vielleicht kannst du deine Meinung zur letzte Meldung beitragen.
Ich kanns nicht einordnen...
Ich kanns nicht einordnen...
Antwort auf Beitrag Nr.: 64.994.982 von Wolgastae am 04.09.20 20:32:05
super, danke👍👍
Zitat von Wolgastae: httVANCOUVER, British Columbia--(BUSINESS WIRE)--Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) (“Sproutly" or the “Company”) is pleased to announce it has secured a private loan (the “Loan”) of $855,000 from Infusion Biosciences Inc. (the “Lender”), a related party of the Company (the “Debt Financing”). The Loan carries an interest rate of 15% per annum accruing and compounding monthly, payable on maturity on or before October 24, 2020 (the “Maturity Date”). The Company anticipates using the proceeds of the Debt Financing to support the Company’s general working capital.ps://www.businesswire.com/news/home/20200827005784/en/
super, danke👍👍
Durchsuchen
